Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study

Leukemia. 2020 Oct;34(10):2794-2797. doi: 10.1038/s41375-020-0798-9. Epub 2020 Mar 17.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Female
  • Humans
  • Incidence
  • Lymphoma, B-Cell / complications*
  • Lymphoma, B-Cell / drug therapy
  • Lymphoma, B-Cell / epidemiology*
  • Male
  • Medicare
  • Neoplasms, Second Primary / epidemiology*
  • Neoplasms, Second Primary / etiology*
  • Population Surveillance
  • Time-to-Treatment
  • United States / epidemiology

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • ibritumomab tiuxetan